Table 2 Base editing enrichment strategies
Strategy | Cells | Target locus | Selection | Editing pre-enrichment | Editing post-enrichment | Fold increase | Ref. |
|---|---|---|---|---|---|---|---|
BE-FLARE | PC9 | BRAF (T57I) | FACS (BFP to GFP) | 9% | 55% | 6.1-fold | [176] |
BE-FLARE | PC9 | BRAF (Q58*) | FACS (BFP to GFP) | 4% | 20% | 5-fold | [176] |
BE-FLARE | PC9 | EGFR (T790) | FACS (BFP to GFP) | 1% | 18% | 18-fold | [176] |
TREE | HEK293T | APOE (R158C) | FACS (BFP to GFP) | 9% | 26% | 2.9-fold | [177] |
TREE | hPSCs | APOE (R158C) | FACS (BFP to GFP) | 6% | 23% | 3.8-fold | [177] |
BIG-TREE | hPSCs | APOE (R158C) | FACS (BFP to GFP) | 10% | 80–90% |  > 8-fold | [178] |
GO | DLD1 | EMX1/FANCF/CTNNB1 | Antibiotic resistance |  < 1% |  ~ 30–60% | 10- to 120-fold | [171] |
GO | Pancreatic organoid | Intergenic region Chr8/APC | Antibiotic resistance |  < 1% | 44% |  > 44-fold | [171] |
Universal toxin-based selection | HEK293T | DPM2/EGFR/EMX1/PCSK9/ DNMT3B | Drug selection | N.A | N.A | 4 to 7-fold | [120] |
Universal toxin-based selection | HEK293T | EMX1/CTLA4/IL2RA/ AAVS1 | Drug selection | N.A | N.A | 6 to 13-fold | [120] |
Universal toxin-based selection | HCT116 | PCSK9 | Drug selection | N.A | N.A | 13-fold | [120] |
ACE | HEK293T | FANCF | FACS | 0.2% 15% | 58% 78% | 290-fold and 5.2-fold | [175] |
BEAR | HEK293T | HEK/CCR5/FANCF/SCN5a | FACS | 3–10% | 20–25% | 2.8 to 4.8-fold | [179] |
BEAR | HEK293T | HEK/CCR5/FANCF/SCN5a | FACS | 5–40% | 12–60% | 1.3 to 2.9-fold | [179] |
BEON | HEK293T | Human site 1 (S1) | FACS | 9.5% ± 4.9% | 70.6% ± 7.3% | 2.4-fold | [172] |
BEON | HEK293T | CAR | FACS | N.A | 37.54% (± 1.27%) | NA | [172] |
BEON | Neuro2A | mTmem5 | FACS | N.A |  ~ 60% | NA | [172] |